GnuBio to Ship Early Version of Sequencer to Montreal Heart Institute
June 14, 2011
GnuBio to Ship Early Version of Sequencer to Montreal Heart Institute
The company has sequenced amplicons from plasmids as well as from clinical targets, including a 477-base amplicon from the p53 gene.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GnuBio Claims Proof of Principle for Sequencing; Plans to Ship Early Commercial Systems by Year-End
April 12, 2011 / In Sequence - GnuBio Licenses Microfluidics, Emulsion Methods for DNA Sequencing from Harvard
August 31, 2010 / In Sequence - Pathogenica Bets on Next-Gen Sequencing for Fast, Multiplexed Pathogen Detection
July 6, 2010 / In Sequence - Targeting Launch of Platform by Year's End, GnuBio Bets on Gene Panels, Replacing Sanger Assays
February 28, 2012 / In Sequence - Montreal Heart Institute Developing GnuBio Sequencing Panel for Sudden Cardiac Death Test
February 1, 2012 / Pharmacogenomics Reporter